Our Mission

The goal of the TBCRC is to conduct innovative, high impact, biologically-driven translational and clinical research.  Our mission is to lessen the burden of breast cancer by using a multidisciplinary approach to discover novel mechanisms of breast cancer pathogenesis and test innovative, basic science-based therapeutic strategies.

Our History

The Translational Breast Cancer Research Consortium (TBCRC) is a collaborative group founded in 2005 to conduct innovative and high-impact clinical trials for breast cancer. The TBCRC is composed of nineteen clinical sites, five core subcommittees/ working groups (WGs) comprised of a Correlative Science WG and four other groups organized around various breast cancer phenotypes (including the Triple Negative WG, the HER2 Resistance WG, the Endocrine Resistance WG, and the Locoregional Disease WG), three interest groups (IGs) including the Pre-Operative Radiation Therapy, Patient Reported Outcomes and the Immuno-Oncology IG, a patient advocate WG, a study coordinator WG, a contracts/ administrators WG, and a Central Office.  Collectively, these groups work together to foster trial development in a collegial environment that enhances cross-institutional collaborations.

Leadership

Central Office

Chief Scientific Officer

Ex Officio Steering Committee Member

Chief Operating Officer

Ex Officio Steering Committee Member

Cindy Morin

Business Manager

Robyn Burns, Ph.D.

Program Manager

Steering Committee

University of North Carolina at Chapel Hill

Dana-Farber/Harvard Cancer Center

MD Anderson Cancer Center

Vanderbilt University

Memorial Sloan-Kettering Cancer Center

University of North Carolina at Chapel Hill

Mayo Clinic Cancer Center

University of Washington School of Medicine/Fred Hutchinson Cancer Research Center

Baylor College of Medicine

Dana-Farber/Harvard Cancer Center

Subcommittee Chairs

Contracts and Administrators Working Group

Christine Gedansky,

Johns Hopkins Kimmel Cancer Center

Cindy Morin,

Johns Hopkins Kimmel Cancer Center

Neha Parikh,

Johns Hopkins Kimmel Cancer Center

Correlative Science Working Group

Andrea Richardson, M.D., Ph.D.,

Johns Hopkins Kimmel Cancer Center

Minetta Liu, M.D.,

Mayo Clinic Cancer Center

Endocrine Resistance Working Group

Claudine Isaacs, M.D.,

Georgetown University

James Rae, Ph.D.,

University of Michigan Comprehensive Cancer Center

HER2 Resistance Working Group

Mothaffar Rimawi, M.D.,

Baylor College of Medicine

Nancy Lin, M.D.,

Dana-Farber/ Harvard Cancer Center

Immuno-Oncology Interest Group

Elizabeth Mittendorf, M.D., Ph.D.,

Dana-Farber/ Harvard Cancer Center

Mary (Nora) Disis, M.D.,

University of Washington School of Medicine/Fred Hutchinson Cancer Research Center

Locoregional Disease Working Group

Alastair Thompson, M.D.,

Baylor College of Medicine

Gaorav Gupta, M.D., Ph.D.,

University of North Carolina at Chapel Hill

Patient Advocate Working Group

Anne Meyn

Susan Rafte

Pre-Operative Radiation Therapy Interest Group

Alice Ho, M.D.,

Dana-Farber/ Harvard Cancer Center

Gaorav Gupta, M.D., Ph.D.,

University of North Carolina at Chapel Hill

PRO Interest Group

Gabrielle Rocque, M.D.,

University of Alabama at Birmingham

Michelle Melisko, M.D.,

University of California San Francisco

Statistical Advisory Committee

Elizabeth Garrett-Mayer, Ph.D.,

ASCO

Sue Hilsenbeck, Ph.D.,

Baylor College of Medicine

Study Coordinator Working Group

Amanda Spratt,

University of Chicago Medical Center

Jennifer Savoie,

Dana-Farber/ Harvard Cancer Center

Pam Hardwick,

University of Alabama at Birmingham

Rometa Pollard,

University of Pittsburgh Cancer Institute

Triple Negative Working Group

Ben Ho Park, M.D., Ph.D.,

Vanderbilt University

Hope Rugo, M.D.,

University of California San Francisco